# A Study of CM313 Injection in Subjects With Systemic Lupus Erythematosus

> **NCT05465707** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Keymed Biosciences Co.Ltd** · enrollment: 40 (estimated)

## Conditions studied

- Systemic Lupus Erythematosus

## Interventions

- **BIOLOGICAL:** CM313 2 mg/kg
- **BIOLOGICAL:** CM313 4 mg/kg
- **BIOLOGICAL:** CM313 8 mg/kg
- **BIOLOGICAL:** CM313 16 mg/kg
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT05465707
- **Lead sponsor:** Keymed Biosciences Co.Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-10-30
- **Primary completion:** 2023-10-30
- **Final completion:** 2023-10-30
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2022-07-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05465707

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05465707, "A Study of CM313 Injection in Subjects With Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05465707. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*